Abstract:Cysteine palmitoylation (S-palmitoylation) is a reversible post-translational modification that is installed by the DHHC family of palmitoyltransferases and is reversed by several acyl protein thioesterases<a href="/articles/s41586-020-2799-2#ref-CR1">1</a>,<a href="/articles/s41586-020-2799-2#ref-CR2">2</a>. Although thousands of human proteins are known to undergo S-palmitoylation, how this modification is regulated to modulate specific biological functions is poorly understood. Here we report that the key T helper 17 (TH17) cell differentiation stimulator, STAT3<a href="/articles/s41586-020-2799-2#ref-CR3">3</a>,<a href="/articles/s41586-020-2799-2#ref-CR4">4</a>, is subject to reversible S-palmitoylation on cysteine 108. DHHC7 palmitoylates STAT3 and promotes its membrane recruitment and phosphorylation. Acyl protein thioesterase 2 (APT2, also known as LYPLA2) depalmitoylates phosphorylated STAT3 (p-STAT3) and enables it to translocate to the nucleus. This palmitoylation–depalmitoylation cycle enhances STAT3 activation and promotes TH17 cell differentiation; perturbation of either palmitoylation or depalmitoylation negatively affects TH17 cell differentiation. Overactivation of TH17 cells is associated with several inflammatory diseases, including inflammatory bowel disease (IBD). In a mouse model, pharmacological inhibition of APT2 or knockout of Zdhhc7—which encodes DHHC7—relieves the symptoms of IBD. Our study reveals not only a potential therapeutic strategy for the treatment of IBD but also a model through which S-palmitoylation regulates cell signalling, which might be broadly applicable for understanding the signalling functions of numerous S-palmitoylation events.

The phosphatase DUSP2 controls the activity of the transcription activator STAT3 and regulates T H 17 differentiation

Phosphatase PP2A is Essential for T H 17 Differentiation

Phosphatase PP2A is essential for TH17 differentiation.

Methyltransferase Setd2 Prevents T Cell-Mediated Autoimmune Diseases Via Phospholipid Remodeling

The Atypical Dual Specificity Phosphatase DUSP15 Regulates Jak1-Mediated STAT3 Activation

The phosphatase DUSP22 inhibits UBR2-mediated K63-ubiquitination and activation of Lck downstream of TCR signalling

HIPK2 directs cell type–specific regulation of STAT3 transcriptional activity in Th17 cell differentiation

The Role of STAT3 in Antigen-Igg Inducing Regulatory CD4+Foxp3+T Cells

TCR Signaling Induces STAT3 Phosphorylation to Promote TH17 Cell Differentiation.

USP1-regulated Reciprocal Differentiation of Th17 Cells and Treg Cells by Deubiquitinating and Stabilizing TAZ.

A STAT3 palmitoylation cycle promotes TH17 differentiation and colitis

Dusp5 Negatively Regulates IL-33-mediated Eosinophil Survival and Function.

USP18 inhibits NF-κB and NFAT activation during Th17 differentiation by deubiquitinating the TAK1-TAB1 complex.

DUSP6 mediates T cell receptor-engaged glycolysis and restrains TFH cell differentiation.

Genome-wide Analysis of STAT3-Mediated Transcription During Early Human Th17 Cell Differentiation.

Identification of the E3 Deubiquitinase Ubiquitin-specific Peptidase 21 (USP21) as a Positive Regulator of the Transcription Factor GATA3

The dual-specificity phosphatase DUSP14 negatively regulates tumor necrosis factor- and interleukin-1-induced nuclear factor-κB activation by dephosphorylating the protein kinase TAK1.

The E3 Deubiquitinase USP17 Is a Positive Regulator of Retinoic Acid-related Orphan Nuclear Receptor γt (RORγt) in Th17 Cells

The Dual-Specificity Phosphatase Dusp14 Negatively Regulates Tumor Necrosis Factor- And Interleukin-1-Induced Nuclear Factor-Kappa B Activation By Dephosphorylating The Protein Kinase Tak1

Deubiquitination of aryl hydrocarbon receptor by USP21 negatively regulates T helper 17 cell differentiation

Cutting Edge: Ubiquitin-Specific Protease 4 Promotes Th17 Cell Function under Inflammation by Deubiquitinating and Stabilizing RORγt